Tyra Biosciences (TYRA) Financials

$9.29 -0.30 (-3.13%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$9.30 +0.01 (+0.05%)

As of 05/23/2025 07:51 PM Eastern

Annual Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-86	-69	-55
Consolidated Net Income / (Loss)	-86	-69	-55
Net Income / (Loss) Continuing Operations	-86	-69	-55
Total Pre-Tax Income	-86	-69	-55
Total Operating Income	-104	-80	-59
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	104	80	59
Selling, General & Admin Expense	24	17	16
Research & Development Expense	80	63	43
Total Other Income / (Expense), net	18	11	3.60
Interest & Investment Income	18	11	3.65
Basic Earnings per Share	($1.51)	($1.62)	($1.32)
Weighted Average Basic Shares Outstanding	57.22M	42.70M	41.88M
Diluted Earnings per Share	($1.51)	($1.62)	($1.32)
Weighted Average Diluted Shares Outstanding	57.22M	42.70M	41.88M
Weighted Average Basic & Diluted Shares Outstanding	53.09M	52.52M	42.44M

This table shows Tyra Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-27	-22	-19	-18	-22	-21	-13	-12	-13	-13
Consolidated Net Income / (Loss)	-26	-24	-19	-18	-23	-21	-13	-12	-13	-13
Net Income / (Loss) Continuing Operations	-26	-24	-19	-18	-23	-21	-13	-12	-13	-13
Total Pre-Tax Income	-26	-24	-19	-18	-23	-21	-13	-12	-13	-13
Total Operating Income	-30	-29	-24	-22	-26	-24	-16	-14	-15	-14
Total Operating Expenses	30	29	24	22	26	24	16	14	15	14
Selling, General & Admin Expense	7.54	5.91	5.54	5.12	4.96	4.69	3.85	3.93	4.62	2.73
Research & Development Expense	22	23	18	17	21	19	12	10	10	11
Total Other Income / (Expense), net	4.15	4.59	4.83	4.13	2.80	2.81	2.74	2.45	2.13	1.14
Interest & Investment Income	4.15	4.59	4.83	4.13	2.80	2.81	2.74	2.45	2.16	1.13
Basic Earnings per Share	($0.43)	($0.41)	($0.32)	($0.35)	($0.54)	($0.49)	($0.31)	($0.28)	($0.30)	($0.30)
Weighted Average Basic Shares Outstanding	57.22M	58.87M	58.67M	52.23M	42.70M	42.87M	42.59M	42.39M	41.88M	42.00M
Diluted Earnings per Share	($0.43)	($0.41)	($0.32)	($0.35)	($0.54)	($0.49)	($0.31)	($0.28)	($0.30)	($0.30)
Weighted Average Diluted Shares Outstanding	57.22M	58.87M	58.67M	52.23M	42.70M	42.87M	42.59M	42.39M	41.88M	42.00M
Weighted Average Basic & Diluted Shares Outstanding	53.09M	50.60M	52.81M	52.54M	52.52M	43.06M	43.01M	42.56M	42.44M	42.20M

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	34	-193	-50
Net Cash From Operating Activities	-70	-50	-50
Net Cash From Continuing Operating Activities	-70	-50	-50
Net Income / (Loss) Continuing Operations	-86	-69	-55
Consolidated Net Income / (Loss)	-86	-69	-55
Depreciation Expense	0.52	0.36	0.30
Non-Cash Adjustments To Reconcile Net Income	17	12	11
Changes in Operating Assets and Liabilities, net	-0.73	6.36	-5.85
Net Cash From Investing Activities	-98	-145	-0.56
Net Cash From Continuing Investing Activities	-98	-145	-0.56
Purchase of Property, Plant & Equipment	-0.66	-0.77	-0.56
Purchase of Investments	-264	-144	0.00
Sale and/or Maturity of Investments	166	0.00	0.00
Net Cash From Financing Activities	202	1.54	0.63
Net Cash From Continuing Financing Activities	202	1.54	0.63
Issuance of Common Equity	202	1.54	0.63
Cash Interest Paid	0.00	0.00	0.00

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-12	4.40	-155	196	-158	-17	-9.29	-9.51	-12	-12
Net Cash From Operating Activities	-20	-18	-10	-22	-14	-17	-9.62	-9.85	-12	-12
Net Cash From Continuing Operating Activities	-20	-18	-10	-22	-14	-17	-9.62	-9.85	-12	-12
Net Income / (Loss) Continuing Operations	-26	-24	-19	-18	-23	-21	-13	-12	-13	-13
Consolidated Net Income / (Loss)	-26	-24	-19	-18	-23	-21	-13	-12	-13	-13
Depreciation Expense	0.14	0.13	0.13	0.12	0.10	0.08	0.09	0.08	0.08	0.08
Non-Cash Adjustments To Reconcile Net Income	5.52	5.97	2.54	2.89	2.94	4.38	2.53	2.43	2.91	1.02
Changes in Operating Assets and Liabilities, net	0.32	0.02	5.77	-6.84	6.26	-0.45	1.04	-0.48	-2.08	-0.81
Net Cash From Investing Activities	6.96	22	-145	18	-144	-0.08	-0.04	-0.04	-0.02	-0.05
Net Cash From Continuing Investing Activities	6.96	22	-145	18	-144	-0.08	-0.04	-0.04	-0.02	-0.05
Purchase of Property, Plant & Equipment	-0.01	-0.05	-0.47	-0.14	-0.60	-0.08	-0.04	-0.04	-0.02	-0.05
Purchase of Investments	-38	-36	-177	-12	-144	-	-	0.00	-	-
Sale and/or Maturity of Investments	45	58	33	30	-	-	-	0.00	-	-
Net Cash From Financing Activities	0.71	0.74	0.37	200	0.32	0.47	0.37	0.38	0.00	0.36
Net Cash From Continuing Financing Activities	0.71	0.74	0.37	200	0.32	0.47	0.37	0.38	0.00	0.36
Issuance of Common Equity	0.71	0.74	0.37	200	0.32	0.47	0.37	0.38	0.00	0.36

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	364	226	266
Total Current Assets	347	212	257
Cash & Equivalents	92	58	251
Short-Term Investments	249	145	0.00
Prepaid Expenses	6.02	8.20	6.08
Plant, Property, & Equipment, net	1.65	1.63	1.08
Total Noncurrent Assets	14	13	7.82
Other Noncurrent Operating Assets	14	13	7.82
Total Liabilities & Shareholders' Equity	364	226	266
Total Liabilities	20	22	8.35
Total Current Liabilities	15	15	5.70
Accounts Payable	0.59	4.66	1.15
Accrued Expenses	14	10	4.42
Other Current Liabilities	0.41	0.28	0.14
Total Noncurrent Liabilities	5.81	6.26	2.65
Other Noncurrent Operating Liabilities	5.81	6.26	2.65
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	343	204	258
Total Preferred & Common Equity	343	204	258
Preferred Stock	0.00	0.00	0.00
Total Common Equity	343	204	258
Common Stock	594	369	354
Retained Earnings	-251	-165	-96
Accumulated Other Comprehensive Income / (Loss)	0.77	0.38	0.00

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	381	392	405	238	250	255	276
Total Current Assets	366	379	391	225	241	247	267
Cash & Equivalents	104	99	254	216	232	242	263
Short-Term Investments	256	274	128	-	-	-	-
Prepaid Expenses	5.48	4.78	8.32	8.98	8.33	5.01	4.26
Plant, Property, & Equipment, net	1.79	1.90	1.59	1.15	1.05	1.05	1.15
Total Noncurrent Assets	13	12	12	13	8.21	7.30	7.37
Other Noncurrent Operating Assets	13	12	12	13	8.21	7.30	7.37
Total Liabilities & Shareholders' Equity	381	392	405	238	250	255	276
Total Liabilities	18	16	15	16	11	6.27	8.23
Total Current Liabilities	12	10	8.72	10	5.41	3.68	5.49
Accounts Payable	1.17	1.58	2.88	2.31	1.44	1.28	2.75
Accrued Expenses	11	8.42	5.47	7.69	3.82	2.26	2.62
Other Current Liabilities	0.40	0.38	0.37	0.15	0.14	0.14	0.13
Total Noncurrent Liabilities	5.93	6.04	6.15	6.04	6.04	2.58	2.74
Other Noncurrent Operating Liabilities	5.93	6.04	6.15	6.04	6.04	2.58	2.74
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	362	376	390	222	239	249	268
Total Preferred & Common Equity	362	376	390	222	239	249	268
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	362	376	390	222	239	249	268
Common Stock	586	578	573	364	359	356	351
Retained Earnings	-226	-202	-183	-142	-121	-108	-83
Accumulated Other Comprehensive Income / (Loss)	1.75	-0.18	-0.01	-	-	-	-

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-30.24%	-35.63%	-124.26%
EBIT Growth	-30.31%	-35.55%	-124.19%
NOPAT Growth	-30.31%	-35.67%	-124.16%
Net Income Growth	-25.09%	-24.96%	-110.41%
EPS Growth	6.79%	-22.73%	30.89%
Operating Cash Flow Growth	-39.16%	0.29%	-111.77%
Free Cash Flow Firm Growth	-47.27%	-3.79%	-152.04%
Invested Capital Growth	115.64%	-88.01%	1,586.74%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-4.05%	-15.36%	-9.49%
EBIT Q/Q Growth	-4.08%	-15.31%	-9.50%
NOPAT Q/Q Growth	-4.08%	-15.31%	-9.45%
Net Income Q/Q Growth	-3.27%	-16.78%	-5.66%
EPS Q/Q Growth	6.79%	-17.39%	-157.14%
Operating Cash Flow Q/Q Growth	-9.51%	-3.19%	-6.24%
Free Cash Flow Firm Q/Q Growth	-12.38%	0.73%	0.00%
Invested Capital Q/Q Growth	-20.76%	-87.83%	45.57%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	83.01%	86.48%	93.81%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-31.60%	-29.92%	-19.77%
Cash Return on Invested Capital (CROIC)	-5,900.19%	-1,353.45%	-730.20%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-31.60%	-29.92%	-19.77%
Return on Equity Simple (ROE_SIMPLE)	-25.20%	-33.85%	-21.46%
Net Operating Profit after Tax (NOPAT)	-73	-56	-41
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.98%	-5.79%	-5.09%
Return On Investment Capital (ROIC_SIMPLE)	-21.25%	-27.40%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-104	-80	-59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-104	-80	-59
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.05	2.92	1.24
Price to Tangible Book Value (P/TBV)	2.05	2.92	1.24
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	211.66	495.45	10.50
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.00	-0.98	-0.99
Leverage Ratio	1.08	1.06	1.02
Compound Leverage Factor	0.89	0.92	0.96
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	19.87	15.42	22.94
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	23.81	13.80	45.13
Quick Ratio	23.40	13.27	44.06
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-74	-50	-48
Operating Cash Flow to CapEx	-10,508.13%	-6,511.56%	-8,995.53%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	1.71	0.79	6.62
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.92	-5.82	7.06
Enterprise Value (EV)	362	393	69
Market Capitalization	703	596	321
Book Value per Share	$6.78	$4.74	$6.11
Tangible Book Value per Share	$6.78	$4.74	$6.11
Total Capital	343	204	258
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-341	-203	-251
Capital Expenditures (CapEx)	0.66	0.77	0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.57	-7.13	0.37
Debt-free Net Working Capital (DFNWC)	333	196	252
Net Working Capital (NWC)	333	196	252
Net Nonoperating Expense (NNE)	14	13	14
Net Nonoperating Obligations (NNO)	-341	-203	-251
Total Depreciation and Amortization (D&A)	0.52	0.36	0.30
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.51)	($1.62)	($1.32)
Adjusted Weighted Average Basic Shares Outstanding	57.22M	42.70M	41.88M
Adjusted Diluted Earnings per Share	($1.51)	($1.62)	($1.32)
Adjusted Weighted Average Diluted Shares Outstanding	57.22M	42.70M	41.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	53.09M	52.52M	42.44M
Normalized Net Operating Profit after Tax (NOPAT)	-73	-56	-41
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-15.84%	-19.25%	-46.98%	-55.78%	-70.55%	-76.13%	-3.59%	3.58%	-51.44%	-105.30%
EBIT Growth	-15.94%	-19.37%	-46.95%	-55.73%	-70.30%	-75.68%	-3.71%	3.44%	-51.50%	-105.27%
NOPAT Growth	-15.94%	-19.37%	-46.95%	-55.73%	-70.67%	-75.62%	-3.80%	3.37%	-51.24%	-105.56%
Net Income Growth	-12.01%	-13.54%	-40.91%	-53.13%	-77.05%	-69.09%	12.08%	19.87%	-29.86%	-88.30%
EPS Growth	20.37%	16.33%	-3.23%	-25.00%	-80.00%	-63.33%	13.89%	22.22%	-109.01%	58.33%
Operating Cash Flow Growth	-44.77%	-4.39%	-6.69%	-123.70%	-12.95%	-40.39%	43.99%	-10.33%	-32.70%	-118.93%
Free Cash Flow Firm Growth	-79.20%	16.45%	7.80%	13.47%	31.03%	-2.35%	6.34%	-103.31%	0.00%	-4,203.92%
Invested Capital Growth	115.64%	-66.89%	-63.52%	4.63%	-88.01%	43.41%	64.42%	639.09%	1,586.74%	207.68%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-3.86%	-21.67%	-5.43%	13.05%	-6.92%	-49.95%	-11.75%	4.80%	-10.41%	11.81%
EBIT Q/Q Growth	-3.90%	-21.55%	-5.42%	12.92%	-6.97%	-49.64%	-11.72%	4.77%	-10.35%	11.66%
NOPAT Q/Q Growth	-3.90%	-21.55%	-5.42%	12.92%	-6.97%	-49.64%	-11.72%	4.57%	-10.08%	11.56%
Net Income Q/Q Growth	-6.47%	-28.41%	-2.80%	20.32%	-7.93%	-59.37%	-11.72%	7.87%	-3.09%	17.13%
EPS Q/Q Growth	-4.88%	-28.13%	8.57%	35.19%	-10.20%	-58.06%	-10.71%	6.67%	0.00%	16.67%
Operating Cash Flow Q/Q Growth	-9.45%	-74.48%	53.43%	-62.78%	21.07%	-78.32%	2.36%	17.80%	1.90%	28.87%
Free Cash Flow Firm Q/Q Growth	-38.67%	-24.70%	21.27%	-31.62%	35.35%	-37.62%	26.11%	-4.91%	4.05%	-25.93%
Invested Capital Q/Q Growth	-20.76%	-3.96%	-69.70%	835.31%	-87.83%	5.83%	-13.12%	7.15%	45.57%	21.33%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	86.04%	83.96%	79.47%	81.50%	89.06%	88.27%	82.88%	82.88%	85.67%	91.71%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-31.60%	-28.66%	-26.32%	-23.63%	-29.92%	-24.17%	-19.54%	-19.40%	-19.77%	-18.13%
Cash Return on Invested Capital (CROIC)	-5,900.19%	-1,514.62%	-1,496.64%	-853.18%	-1,353.45%	-913.04%	-882.83%	-695.48%	-730.20%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-31.60%	-28.66%	-26.32%	-23.63%	-29.92%	-24.17%	-19.54%	-19.40%	-19.77%	-18.13%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-23.11%	-21.51%	-19.35%	0.00%	-26.65%	-21.19%	-21.05%	0.00%	-19.56%
Net Operating Profit after Tax (NOPAT)	-21	-20	-16	-16	-18	-17	-11	-10	-11	-9.55
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-1.75%	-1.39%	-0.74%	-0.82%	-2.15%	-1.83%	-0.81%	-0.69%	-0.86%	-1.02%
Return On Investment Capital (ROIC_SIMPLE)	-6.06%	-	-	-	-8.78%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-30	-29	-24	-22	-26	-24	-16	-14	-15	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-28	-23	-22	-26	-24	-16	-14	-15	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.05	3.43	2.23	2.21	2.92	2.67	3.04	2.74	1.24	1.38
Price to Tangible Book Value (P/TBV)	2.05	3.43	2.23	2.21	2.92	2.67	3.04	2.74	1.24	1.38
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	211.66	408.41	207.53	64.57	495.45	57.78	79.95	62.10	10.50	23.26
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.00	-0.99	-0.99	-0.98	-0.98	-0.98	-0.98	-0.99	-0.99	-1.00
Leverage Ratio	1.08	1.06	1.05	1.03	1.06	1.05	1.04	1.03	1.02	1.03
Compound Leverage Factor	0.93	0.89	0.83	0.84	0.95	0.93	0.86	0.85	0.88	0.94
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	20.54	40.73	30.91	35.09	16.22	21.87	38.26	65.68	23.48	27.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	23.81	29.55	36.46	44.83	13.80	22.14	44.54	67.00	45.13	48.73
Quick Ratio	23.40	29.11	36.00	43.88	13.27	21.25	43.00	65.64	44.06	47.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-22	-16	-13	-16	-12	-19	-14	-18	-18	-18
Operating Cash Flow to CapEx	-326,500.00%	-34,419.23%	-2,182.55%	-16,197.06%	-2,244.11%	-20,656.63%	-22,360.47%	-24,017.07%	-57,047.62%	-25,441.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1.71	2.16	2.25	7.42	0.79	6.52	6.16	7.09	6.62	4.55
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.92	-4.36	-3.91	0.33	-5.82	1.97	2.41	8.40	7.06	8.77
Enterprise Value (EV)	362	881	466	479	393	377	492	440	69	106
Market Capitalization	703	1,241	840	861	596	592	725	682	321	369
Book Value per Share	$6.78	$6.86	$7.16	$7.42	$4.74	$5.17	$5.61	$5.86	$6.11	$6.38
Tangible Book Value per Share	$6.78	$6.86	$7.16	$7.42	$4.74	$5.17	$5.61	$5.86	$6.11	$6.38
Total Capital	343	362	376	390	204	222	239	249	258	268
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-341	-360	-374	-382	-203	-216	-232	-242	-251	-263
Capital Expenditures (CapEx)	0.01	0.05	0.47	0.14	0.60	0.08	0.04	0.04	0.02	0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.57	-6.89	-5.60	-0.40	-7.13	-1.17	2.93	1.33	0.37	-1.23
Debt-free Net Working Capital (DFNWC)	333	353	368	382	196	214	235	243	252	262
Net Working Capital (NWC)	333	353	368	382	196	214	235	243	252	262
Net Nonoperating Expense (NNE)	4.77	3.99	2.23	2.57	4.89	4.38	2.06	1.85	2.38	2.96
Net Nonoperating Obligations (NNO)	-341	-360	-374	-382	-203	-216	-232	-242	-251	-263
Total Depreciation and Amortization (D&A)	0.14	0.13	0.13	0.12	0.10	0.08	0.09	0.08	0.08	0.08
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.43)	($0.41)	($0.32)	($0.35)	($0.54)	($0.49)	($0.31)	($0.28)	($0.30)	($0.30)
Adjusted Weighted Average Basic Shares Outstanding	57.22M	58.87M	58.67M	52.23M	42.70M	42.87M	42.59M	42.39M	41.88M	42.00M
Adjusted Diluted Earnings per Share	($0.43)	($0.41)	($0.32)	($0.35)	($0.54)	($0.49)	($0.31)	($0.28)	($0.30)	($0.30)
Adjusted Weighted Average Diluted Shares Outstanding	57.22M	58.87M	58.67M	52.23M	42.70M	42.87M	42.59M	42.39M	41.88M	42.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	53.09M	50.60M	52.81M	52.54M	52.52M	43.06M	43.01M	42.56M	42.44M	42.20M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-20	-16	-16	-18	-17	-11	-10	-11	-9.55
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Tyra Biosciences' Financials

When does Tyra Biosciences's fiscal year end?

According to the most recent income statement we have on file, Tyra Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Tyra Biosciences' net income changed over the last 2 years?

Tyra Biosciences' net income appears to be on an upward trend, with a most recent value of -$86.48 million in 2024, rising from -$55.33 million in 2022. The previous period was -$69.13 million in 2023. See Tyra Biosciences' forecast for analyst expectations on what’s next for the company.

What is Tyra Biosciences's operating income?

Tyra Biosciences's total operating income in 2024 was -$104.18 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $104.18 million

How has Tyra Biosciences revenue changed over the last 2 years?

Over the last 2 years, Tyra Biosciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Tyra Biosciences have?

Tyra Biosciences' total liabilities were at $20.41 million at the end of 2024, a 5.5% decrease from 2023, and a 144.3% increase since 2022.

How much cash does Tyra Biosciences have?

In the past 2 years, Tyra Biosciences' cash and equivalents has ranged from $58.01 million in 2023 to $251.21 million in 2022, and is currently $91.97 million as of their latest financial filing in 2024.

How has Tyra Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Tyra Biosciences' book value per share changed from 6.11 in 2022 to 6.78 in 2024, a change of 11.0%.

Related Companies

This page (NASDAQ:TYRA) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Financials

Frequently Asked Questions About Tyra Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Financials

Annual Income Statements for Tyra Biosciences

Quarterly Income Statements for Tyra Biosciences

Annual Cash Flow Statements for Tyra Biosciences

Quarterly Cash Flow Statements for Tyra Biosciences

Annual Balance Sheets for Tyra Biosciences

Quarterly Balance Sheets for Tyra Biosciences

Annual Metrics And Ratios for Tyra Biosciences

Quarterly Metrics And Ratios for Tyra Biosciences

Frequently Asked Questions About Tyra Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools